Avidity Biosciences
RNA
$6.90
Share price
-2.27%
Change (1 day)
-60.46%
Change (1 year)
Categories
Operating Margin for Avidity Biosciences (RNA)
Operating Margin as of September 2023 (TTM): -1,886.32%
According to Avidity Biosciences's latest financial reports and stock price the company's current Operating Margin is -1,886.32%. At the end of 2021 the company had an Operating Margin of -1,265.38%.
Operating Margin history for Avidity Biosciences from 2020 to 2022
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2021 | -1,265.38% | 93.62% |
| 2020 | -653.53% | -38.73% |
| 2019 | -1,066.58% | -63.96% |
| 2018 | -2,959.37% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 34.61% | -101.83% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 22.54% | -101.19% | 🇬🇧 UK |
 Sarepta Therapeutics
SRPT | -88.19% | -95.32% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | -84.20% | -95.54% | 🇺🇸 USA |
 Fate Therapeutics
FATE | -191.80% | -89.83% | 🇺🇸 USA |
 Acorda Therapeutics
ACOR | -84.50% | -95.52% | 🇺🇸 USA |
 Acceleron Pharma XLRN | -226.57% | -87.99% | 🇺🇸 USA |
 Catalyst Pharmaceuticals CPRX | 48.88% | -102.59% | 🇺🇸 USA |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.